Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W FRY

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
Advances in Experimental Medicine and Biology|January 1, 1983
Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytesD W Fry, D A Gewirtz, J C Yalowich, et al.
Biochemical Pharmacology|October 1, 1985
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)D W Fry, T J Boritzki, J A Besserer, et al.
Molecular and Cellular Biology|June 22, 1999
Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2J D Owen, P J Ruest, D W Fry, et al.
Cancer Research|July 1, 1980
Relationship between membrane transport of methotrexate and endogenous cyclic adenosine 3':5'-monophosphate in the Ehrlich ascites tumorJ C White, R A Carchman, D W Fry, et al.
Cancer Letters|June 1, 1986
Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301UW D Klohs, R W Steinkampf, J A Besserer, et al.
Seminars in Oncology|April 1, 1988
Preclinical studies with trimetrexate: a review of conclusions and unanswered questionsR C Jackson, W R Leopold, K L Hamelehle, et al.
Journal of Medicinal Chemistry|July 1, 1990
Potent inhibition of thymidylate synthase by two series of nonclassical quinazolinesD J McNamara, E M Berman, D W Fry, et al.
Bioorganic & Medicinal Chemistry|December 1, 1995
Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolinesA J Bridges, D R Cody, H Zhou, et al.
Peptides|January 1, 1994
Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1D W Fry, A McMichael, J Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
Advances in Experimental Medicine and Biology|January 1, 1983
Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytesD W Fry, D A Gewirtz, J C Yalowich, et al.
Biochemical Pharmacology|October 1, 1985
In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)D W Fry, T J Boritzki, J A Besserer, et al.
Molecular and Cellular Biology|June 22, 1999
Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2J D Owen, P J Ruest, D W Fry, et al.
Cancer Research|July 1, 1980
Relationship between membrane transport of methotrexate and endogenous cyclic adenosine 3':5'-monophosphate in the Ehrlich ascites tumorJ C White, R A Carchman, D W Fry, et al.
Cancer Letters|June 1, 1986
Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301UW D Klohs, R W Steinkampf, J A Besserer, et al.
Seminars in Oncology|April 1, 1988
Preclinical studies with trimetrexate: a review of conclusions and unanswered questionsR C Jackson, W R Leopold, K L Hamelehle, et al.
Journal of Medicinal Chemistry|July 1, 1990
Potent inhibition of thymidylate synthase by two series of nonclassical quinazolinesD J McNamara, E M Berman, D W Fry, et al.
Bioorganic & Medicinal Chemistry|December 1, 1995
Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolinesA J Bridges, D R Cody, H Zhou, et al.
Peptides|January 1, 1994
Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-gamma 1D W Fry, A McMichael, J Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.
Pageof 9